Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Paclitaxel

Paclitaxel

Paclitaxel is a naturally occurring compound derived from the bark of the Pacific yew tree (Taxus brevifolia).
It is a potent anti-cancer agent that functions by inhibiting cell division through the stabilization of microtubules.
Paclitaxel has been approved for the treatment of a variety of solid tumors, including ovarian, breast, lung, and Kaposi's sarcoma.
Researchers can leverage the PubCompare.ai platform to discover optimized Paclitaxel research protocols from literature, pre-prints, and patents, and identiry the most reproducible and accuarate protocols for their studies, improving the quality and efficiency of their Paclitaxel-related research.

Most cited protocols related to «Paclitaxel»

1
Breast Cancer Gene Expression Profiling
Gene-expression data from 230 stage I to III breast cancers, without individual patient identifiers, were provided to the MAQC project by the University of Texas M.D. Anderson Cancer Center (MDACC) Breast Cancer Pharmacogenomic Program. Gene-expression results were generated from fine-needle aspiration specimens of newly diagnosed breast cancers before any therapy. The biopsy specimens were collected sequentially during a prospective pharmacogenomic marker discovery study approved by the institutional review board between 2000 and 2008. These specimens represent 70% to 90% pure neoplastic cells with minimal stromal contamination [12 (link)]. All patients signed informed consent for genomic analysis of their cancers. Patients received 6 months of preoperative (neoadjuvant) chemotherapy including paclitaxel, 5-fluorouracil, cyclophosphamide, and doxorubicin, followed by surgical resection of the cancer. Response to preoperative chemotherapy was categorized as a pathologic complete response (pCR = no residual invasive cancer in the breast or lymph nodes) or residual invasive cancer (RD). The prognostic value of pCR has been discussed extensively in the medical literature [13 (link)]. Genomic analyses of subsets of this sequentially accrued patient population were reported previously [9 (link),14 (link),15 (link)]. For each endpoint, we used the first 130 cases as a training set to develop prediction models, and the next 100 cases were set aside as independent validation set. Table 1 and Additional file 1 show patient and sample characteristics in the two data sets.
Popovici V., Chen W., Gallas B.G., Hatzis C., Shi W., Samuelson F.W., Nikolsky Y., Tsyganova M., Ishkin A., Nikolskaya T., Hess K.R., Valero V., Booser D., Delorenzi M., Hortobagyi G.N., Shi L., Symmans W.F, & Pusztai L. (2010). Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research : BCR, 12(1), R5.
Full text: Click here
Publication 2010
Aspiration Biopsy, Fine-Needle Biopsy Breast Carcinoma Cells Cyclophosphamide Doxorubicin Ethics Committees, Research Fluorouracil Gene Expression Genome Malignant Neoplasm of Breast Malignant Neoplasms Neoadjuvant Chemotherapy Neoplasms Nodes, Lymph Operative Surgical Procedures Paclitaxel Patients Pharmacogenomic Analysis Pharmacotherapy Residual Cancer Therapeutics
2
High-content Imaging of Cell Response to Drugs
MCF 10A-H2B-mCherry cells were plated at densities that ranged from 156 to 5000 cells per well in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and grown for 24 hours. Cells were treated with a dilution series of drugs using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug addition in an Operetta (Perkin Elmer) for high content imaging system equipped with a live-cell chamber over a period of 72 hours.
In the case of methotrexate and oligomycin, 1250 cells were plated in 20–120 µl of media per well, treated with a dilution series of drug, and imaged for 72 hours.
In the case of linsitinib, cells were treated with a dilution series of linsitinib either with or without 10µM batimastat using a D300 Digital Dispenser and imaged in an IncuCyte ZOOM live cell imager (Essen Bioscience) for an additional 72 hours.
In the case of paclitaxel, cells were treated with a dilution series of paclitaxel and 200 nM of NucView 488 caspase 3 substrate (Biotium) using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug in an IncuCyte ZOOM live cell imager (Essen Bioscience) for an additional 72 hours. For immunofluorescence experiments, cells were grown for 24 hours and then treated with a dilution series of paclitaxel using a D300 Digital Dispenser (Hewlett-Packard) and incubated for 3, 6, 12, and 24 hours. Cells were fixed for 30 min in 3% formaldehyde, permeabilized for 30 min in phosphate buffered saline (PBS) with 0.3% Triton X-100 (Sigma-Aldrich), washed twice in PBS with 0.1% Tween 20 (Sigma-Aldrich; PBS-T), and blocked for 60 min with Odyssey blocking buffer. Anti-active Caspase-3 antibody (BD Biosciences) was diluted 1:1000 in Odyssey blocking buffer and incubated for 16 h at 4°C. Cells were washed three times in PBS-T for 5 min and incubated with Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody for 60 min at room. Cells were washed two times in PBS-T, once with PBS, and stained for 30 min with whole cell stain (Thermo Fisher Scientific) and Hoechst (Thermo Fisher Scientific), and washed three times in PBS.
Hafner M., Niepel M., Chung M, & Sorger P.K. (2016). Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature methods, 13(6), 521-527.
Publication 2016
alexa fluor 488 Antibodies, Anti-Idiotypic batimastat Cardiac Arrest Caspase Caspase 3 Cells Fingers Formaldehyde Goat Immunofluorescence linsitinib Methotrexate Oligomycins Paclitaxel Pharmaceutical Preparations Phosphates Rabbits Saline Solution Stains Technique, Dilution Triton X-100 Tween 20
3
Real-time Cell Proliferation and Cytotoxicity
Experiments were carried out using the xCELLigence RTCA DP instrument (Roche Diagnostics GmbH, Mannheim, Germany) which was placed in a humidified incubator at 37°C and 5% CO2.
Cell proliferation and cytotoxicity experiments were performed using modified 16-well plates (E-plate, Roche Diagnostics GmbH, Mannheim, Germany). Microelectrodes were attached at the bottom of the wells for impedance-based detection of attachment, spreading and proliferation of the cells. Initially, 100 µL of cell-free growth medium (10% FBS) was added to the wells. After leaving the devices at room temperature for 30 min, the background impedance for each well was measured. Cells were harvested from exponential phase cultures by a standardized detachment procedure using 0.05% Trypsin-EDTA (Invitrogen NV/SA, Merelbeke, Belgium) and counted automatically with a Scepter 2.0 device (Merck Millipore SA/NV, Overijse, Belgium), Fifty µL of the cell suspension was seeded into the wells (20, 40, 80, 100, 200, 400 and 800 cells/well for proliferation, 1000 cells/well for cytotoxicity experiments). The cell concentrations of 20, 100, 200 and 400 cells/well were considered for correlation with the SRB method described below. After leaving the plates at room temperature for 30 min to allow cell attachment, in accordance with the manufacturer's guidelines, they were locked in the RTCA DP device in the incubator and the impedance value of each well was automatically monitored by the xCELLigence system and expressed as a Cell Index value (CI). Water was added to the space surrounding the wells of the E-plate to avoid interference from evaporation. For proliferation assays, the cells were incubated during ten days in growth medium (10% FBS) and CI was monitored every 15 min during the first six hours, and every hour for the rest of the period. Two replicates of each cell concentration were used in each test. For cytotoxicity experiments, CI of each well was automatically monitored with the xCELLigence system every 15 min during the overnight recovery period. Twenty-four hours after cell seeding, cells were treated during a period of 72 hours with paclitaxel (0, 1, 2, 5, 10, 20, 50 and 100 nM) dissolved in phosphate buffered saline (PBS). PBS alone was added to control wells. Each concentration was tested in duplicate within the same experiment. CI was monitored every 15 min during the experiment. Three days after the start of treatment with paclitaxel, CI measurement was ended.
Limame R., Wouters A., Pauwels B., Fransen E., Peeters M., Lardon F., De Wever O, & Pauwels P. (2012). Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays. PLoS ONE, 7(10), e46536.
Full text: Click here
Publication 2012
Biological Assay Cell-Matrix Junction Cell Proliferation Cells Culture Media Cytotoxin Diagnosis Edetic Acid Medical Devices Microelectrodes Paclitaxel Phosphates Ribavirin Saline Solution Trypsin
4
High-content Imaging of Cell Response to Drugs
MCF 10A-H2B-mCherry cells were plated at densities that ranged from 156 to 5000 cells per well in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and grown for 24 hours. Cells were treated with a dilution series of drugs using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug addition in an Operetta (Perkin Elmer) for high content imaging system equipped with a live-cell chamber over a period of 72 hours.
In the case of methotrexate and oligomycin, 1250 cells were plated in 20–120 µl of media per well, treated with a dilution series of drug, and imaged for 72 hours.
In the case of linsitinib, cells were treated with a dilution series of linsitinib either with or without 10µM batimastat using a D300 Digital Dispenser and imaged in an IncuCyte ZOOM live cell imager (Essen Bioscience) for an additional 72 hours.
In the case of paclitaxel, cells were treated with a dilution series of paclitaxel and 200 nM of NucView 488 caspase 3 substrate (Biotium) using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug in an IncuCyte ZOOM live cell imager (Essen Bioscience) for an additional 72 hours. For immunofluorescence experiments, cells were grown for 24 hours and then treated with a dilution series of paclitaxel using a D300 Digital Dispenser (Hewlett-Packard) and incubated for 3, 6, 12, and 24 hours. Cells were fixed for 30 min in 3% formaldehyde, permeabilized for 30 min in phosphate buffered saline (PBS) with 0.3% Triton X-100 (Sigma-Aldrich), washed twice in PBS with 0.1% Tween 20 (Sigma-Aldrich; PBS-T), and blocked for 60 min with Odyssey blocking buffer. Anti-active Caspase-3 antibody (BD Biosciences) was diluted 1:1000 in Odyssey blocking buffer and incubated for 16 h at 4°C. Cells were washed three times in PBS-T for 5 min and incubated with Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody for 60 min at room. Cells were washed two times in PBS-T, once with PBS, and stained for 30 min with whole cell stain (Thermo Fisher Scientific) and Hoechst (Thermo Fisher Scientific), and washed three times in PBS.
Hafner M., Niepel M., Chung M, & Sorger P.K. (2016). Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature methods, 13(6), 521-527.
Publication 2016
alexa fluor 488 Antibodies, Anti-Idiotypic batimastat Cardiac Arrest Caspase Caspase 3 Cells Fingers Formaldehyde Goat Immunofluorescence linsitinib Methotrexate Oligomycins Paclitaxel Pharmaceutical Preparations Phosphates Rabbits Saline Solution Stains Technique, Dilution Triton X-100 Tween 20
5
Paclitaxel-induced Neuropathic Pain in Mice

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Allodynia AM 630 AM 1710 Animals antagonists Cardiac Arrest CCL2 protein, human Chemokine Common Cold cremophor Cytokine Endocannabinoids fatty acid amide hydrolase Genotype Inflammation Interleukin-1 beta Mice, Inbred C57BL Monoacylglycerol Lipases Mus Opioid Receptor Paclitaxel Receptor, Cannabinoid, CB1 Receptor, Cannabinoid, CB2 Rectum Rimonabant RNA, Messenger Tumor Necrosis Factor-alpha Withdrawal Symptoms

Most recents protocols related to «Paclitaxel»

1
Targeted Paclitaxel Nanoparticle Cytotoxicity
Not available on PMC !

Example 5

2F2B mouse endothelial cells (ATCC, Manassas, Va., USA) were incubated for 2 days in media, upregulated with 10 nM nicotine or 10 μM angiotensin II to express αvβ3 integrin. The cells may then be exposed to integrin-targeted versus nontargeted paclitaxel-GNB nanoparticle treatments with varying drug loads (0.5 to 5 mole %). The cells were also exposed to equivalent amounts of free drug for 30 minutes as a control. Unbound nanoparticles or unabsorbed drug was washed from wells, and cultures were grown for 6 days, and attached viable cell numbers were counted. The number of cells was significantly decreased when treated with paclitaxel-PC prodrug nanoparticles (PC-PTXL), versus equivalent amounts of free Taxol, αvβ3 integrin-targeted nanoparticles alone, or saline (FIG. 9).

US11872313B2. Prodrug compositions, prodrug nanoparticles, and methods of use thereof (2024-01-16). Washington University [US]. Inventors: Gregory M. Lanza [US], Dipanjan Pan [US].
Full text: Click here
Patent 2024
130-nm albumin-bound paclitaxel Angiotensin II Cells Endothelial Cells Integrins Mus Nevus Nicotine Paclitaxel Pharmaceutical Preparations Prodrugs Saline Solution Taxol
2
Anti-Ror2 Antibody-Drug Conjugate Reduces Tumor Size
Not available on PMC !

Example 2

The anti-Ror2 antibody of the present invention was conjugated to a model toxin (e.g., paclitaxel) to produce a conditionally active antibody-drug conjugate (Ror2-CAB-ADC).

Tumors were induced in mice by injection of MDA-MB-436 tumor cells to produce xenografted mice. The Ror2-CAB-ADC was then injected into the xenografted mice at a dose of 0.3 or 1 mg/kg once a week for 2 weeks. The controls used in this study included PBS buffer as vehicle and the toxin alone (paclitaxel). The study showed that the Ror2-CAB-ADC provided a significantly greater reduction in the size of the tumor, in comparison with the controls (FIGS. 7A-7C). The results for the 0.3 mg/kg dosage group are presented in FIG. 7B and the results for the 1 mg/kg dosage group are presented in FIG. 7C. This study showed that the anti-Ror2 antibody conjugated with toxin is effective in reducing tumor size.

US11879011B2. Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof (2024-01-23). BioAtla, Inc. [US]. Inventors: Jay M. Short [US], Hwai Wen Chang [US], Gerhard Frey [US].
Full text: Click here
Patent 2024
Anti-Antibodies Antibodies, Anti-Idiotypic Antibody-Drug Conjugates Buffers Cells Mus Neoplasms Paclitaxel ROR2 protein, human Toxins, Biological
3
Anti-angiogenic Nanomedicine Delivery
Not available on PMC !

Example 2

Anti-angiogenesis treatment with integrin-targeted doxorubicin prodrug and paclitaxel prodrug PFC nanoparticles was demonstrated using an in vivo Matrigel plug model in rats. The therapeutic response was assessed using MRI neovascular mapping at 3 T with αvβ3 integrin-targeted paramagnetic PFC nanoparticles (FIG. 3). Angiogenesis was decreased by both treatment formulations relative to control. Similar results were obtained in vivo with the Vx2 tumor model in rabbits using paclitaxel prodrug (FIG. 4). Therefore, in contradistinction to prior research that showed loss of paclitaxel or doxorubicin during in vitro dissolution, the phospholipid prodrug forms were retained in circulation, delivered to the target cell, released enzymatically and exerted the intended antiproliferative effects.

US11872313B2. Prodrug compositions, prodrug nanoparticles, and methods of use thereof (2024-01-16). Washington University [US]. Inventors: Gregory M. Lanza [US], Dipanjan Pan [US].
Full text: Click here
Patent 2024
angiogen Cells Doxorubicin Integrins matrigel Neoplasms Oryctolagus cuniculus Paclitaxel Pathologic Neovascularization Phospholipids Prodrugs Rattus
4
Paclitaxel Prodrug Synthesis and Purification
Not available on PMC !

Example 4

Paclitaxel prodrug was synthesized following a five-step synthesis process and purified by column chromatography (FIG. 8). Briefly, commercially available paclitaxel (Avachem Scientific, Inc.) was treated with succinic anhydride in the presence of pyridine to give 2′-succinyl paclitaxel. NHS ester (6) of this intermediate may be obtained by reaction with N-succinimidyl diphenylphosphate (SDPP). The ester was treated with an excess of mono-Boc-ethylene diamine at low temperature followed by deprotection of the tert-Boc. A flexible, linear diamine (1,3-diamino propane) was chosen to reduce the steric hindrance. Finally, the paclitaxel amine was subjected to reductive amination with ALDO PC (or PE) to produce paclitaxel prodrugs (7).

US11872313B2. Prodrug compositions, prodrug nanoparticles, and methods of use thereof (2024-01-16). Washington University [US]. Inventors: Gregory M. Lanza [US], Dipanjan Pan [US].
Full text: Click here
Patent 2024
Amination Amines Anabolism Chromatography Cold Temperature Diamines Esters Ethylenediamines Paclitaxel Prodrugs Propane Pyridines succinic anhydride TERT protein, human
5
Systemic Treatments for Advanced Squamous NSCLC
The target population was Chinese adults (aged ≥ 18 years) who had pathologically confirmed stage IIIB–IV wild-type sq-NSCLC with unlimited PD-L1 expression. The population received no previous systemic therapy. We modeled a hypothetical cohort with the same baseline characteristics as the patients enrolled in the original clinical trials. For dosage calculation, the body surface area and creatinine clearance rate were assumed as 1.72 m2 and 70 ml/min (22 (link)). According to the CSCO 2022 (21 ), the first-level recommended first-line regimens for performance status (PS) 0–1 patients with advanced sq-NSCLC and unlimited PD-L1 expression include cisplatin or carboplatin combined with gemcitabine, docetaxel, or paclitaxel (standard chemotherapy), nedaplatin combined with docetaxel (N + C), paclitaxel and platinum combined with pembrolizumab (P + C), paclitaxel and platinum combined with tislelizumab (T + C), paclitaxel and platinum combined with camrelizumab (CA + C), platinum combined with gemcitabine and sintilimab (SI + C), paclitaxel and platinum combined with sugemalimab (SU + C). Among these seven first-line therapies, T + C, CA + C, SI + C, and SU + C were newly approved for sq-NSCLC since 2021 in China. Nivolumab, tislelizumab and docetaxel are first-level recommended second-line treatments options for these patients, and tislelizumab was newly approved in 2022 for second-line treatment of sq-NSCLC. Because of the possible resistance among PD-1/PD-L1 drugs, few clinical applications and evidence, we did not consider cases where immune checkpoint inhibitors were used in the first- and second-line treatments simultaneously. Therefore, we assessed 11 treatment strategies (see Figure 1): 1. first-line N + C followed by second-line docetaxel (ND); 2. first-line N + C followed by second-line tislelizumab (NT); 3. first-line N + C followed by second-line nivolumab (NN) (16 (link)); 4. first-line standard chemotherapy followed by second-line docetaxel (CD); 5. first-line standard chemotherapy followed by second-line tislelizumab (CT); 6. first-line standard chemotherapy followed by second-line nivolumab (CN) (10 (link)–13 (link), 16 (link), 20 (link)); 7. first-line P + C followed by second-line docetaxel (PED) (13 (link)); 8. first-line SI + C followed by second-line docetaxel (SID) (12 (link)); 9. first-line CA + C followed by second-line docetaxel (CAD) (11 (link)); 10. first-line T + C followed by second-line docetaxel (TID) (20 (link)); 11. first-line SU + C followed by second-line docetaxel (SUD) (10 (link)). According to randomized clinical trials (RCTs) (23 (link), 24 (link)), clinical diagnosis, and treatment experience (25 (link), 26 (link)), the PS of patients with advanced sq-NSCLC tends to be poor after two-line active treatments. Therefore, the best supportive treatment (BSC) accounts for the largest proportion of third-line treatment, surpassing sum of other active treatments' proportions. Thus, patients with disease progression after the first- and second-line treatments were assumed to receive the BSC in this model. Standard chemotherapy and docetaxel were used as comparators for first-line and second-line treatments, respectively. We explored the impact of uncertainty about the third-line treatment on the results by scenario analysis. Specific medication, dosages, treatment durations are provided in the Supplementary material 1.
Zhao M., Shao T., Chi Z, & Tang W. (2023). Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. Frontiers in Public Health, 11, 1051484.
Full text: Click here
Publication 2023
Adult Body Surface Area camrelizumab Carboplatin CD274 protein, human Chinese Cisplatin Creatinine Diagnosis Disease Progression Docetaxel Gemcitabine Immune Checkpoint Inhibitors LINE-1 Elements Metabolic Clearance Rate nedaplatin Nivolumab Non-Small Cell Lung Carcinoma Paclitaxel Patients pembrolizumab Pharmaceutical Preparations Pharmacotherapy Platinum Resistance, Drug sintilimab Target Population tislelizumab Treatment Protocols

Top products related to «Paclitaxel»

1
Paclitaxel by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Macao, Japan, Sao Tome and Principe, Canada, Poland, Spain, Israel, Australia, Switzerland, Italy
Paclitaxel is a pharmaceutical compound used in the production of various cancer treatment medications. It functions as a microtubule-stabilizing agent, which plays a crucial role in the development and regulation of cells. Paclitaxel is a key ingredient in the manufacture of certain anti-cancer drugs.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
4
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
5
Paclitaxel by Selleck Chemicals
Sourced in United States, China, Germany
Paclitaxel is a chemical compound commonly used in laboratory research. It functions as a mitotic inhibitor, which means it interferes with the cell division process. Paclitaxel is often utilized in experiments studying cell biology and cancer research.
6
Doxorubicin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel
Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.
7
Nocodazole by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Sao Tome and Principe, Canada, China, Switzerland, France, Poland, Macao, Australia
Nocodazole is a synthetic compound that acts as a microtubule-destabilizing agent. It functions by binding to and disrupting the polymerization of microtubules, which are essential components of the cytoskeleton in eukaryotic cells. This property makes Nocodazole a valuable tool in cell biology research for studying cell division, cell motility, and other cellular processes that rely on the dynamics of the microtubule network.
8
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
9
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
10
Methyl thiazolyl tetrazolium (mtt) by Merck Group
Sourced in United States, Germany, Italy, China, United Kingdom, Sao Tome and Principe, Macao, France, India, Switzerland, Japan, Poland, Spain, Belgium, Canada, Australia, Brazil, Ireland, Israel, Hungary, Austria, Singapore, Egypt, Czechia, Netherlands, Sweden, Finland, Saudi Arabia, Portugal
MTT is a colorimetric assay used to measure cell metabolic activity. It is a lab equipment product developed by Merck Group. MTT is a tetrazolium dye that is reduced by metabolically active cells, producing a colored formazan product that can be quantified spectrophotometrically.

More about "Paclitaxel"

Paclitaxel, also known as Taxol, is a chemotherapeutic agent derived from the bark of the Pacific yew tree (Taxus brevifolia).
It is a potent anti-cancer drug that works by stabilizing microtubules, a key component of the cell division process.
Paclitaxel has been approved for the treatment of a variety of solid tumors, including ovarian, breast, lung, and Kaposi's sarcoma.
Researchers can leverage the PubCompare.ai platform to discover optimized Paclitaxel research protocols from literature, pre-prints, and patents.
This AI-driven platform helps identify the most reproducible and accurate Paclitaxel protocols, improving the quality and efficiency of Paclitaxel-related research.
In addition to Paclitaxel, researchers may also work with other compounds like Fetal Bovine Serum (FBS), Cisplatin, Dimethyl Sulfoxide (DMSO), Doxorubicin, Nocodazole, Penicillin/Streptomycin, and RPMI 1640 medium.
These substances are commonly used in cell culture and drug testing experiments.
The MTT assay is a widely used method for measuring cell viability and proliferation, which can be useful in Paclitaxel-related studies.
By leveraging the insights and tools provided by PubCompare.ai, researchers can improve the reproducibility and accuracy of their Paclitaxel research, leading to more reliable and impactful findings.